GLUE
Monte Rosa Therapeutics Inc.
$19.20
+$0.39(+2.07%)
60
Overall
60
Value
83
Tech
39
Quality
Market Cap
$812.02M
Volume
694.91K
52W Range
$3.90 - $25.77
Target Price
$32.33
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | -- | -- | $75.6M | $123.7M | ||
| Total Revenue | -- | -- | -- | $75.6M | $123.7M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | -- | -- | $75.6M | $123.7M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $72.9M | $112.4M | $143.3M | $156.7M | $177.9M | ||
| Research & Development | $57.2M | $85.1M | $110.9M | $121.6M | $141.5M | ||
| Research Expense | $57.2M | $85.1M | $110.9M | $121.6M | $141.5M | ||
| Selling, General & Administrative | $15.7M | $27.8M | $32.0M | $35.2M | $36.4M | ||
| General & Administrative Expenses | $15.7M | $27.8M | $32.0M | $35.2M | $36.4M | ||
| Salaries & Wages | $426.0K | $568.0K | $19.6M | $22.2M | -- | ||
| Depreciation & Amortization | $2.1M | $3.7M | $6.2M | $8.1M | -- | ||
| Depreciation & Amortization | $2.1M | $3.7M | $6.2M | -- | -- | ||
| Amortization | -- | $3.3M | $2.1M | -- | -- | ||
| Other Operating Expenses | $-1.3M | -- | $-2.9M | -- | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-72.9M | $-112.4M | $-143.3M | $-81.1M | $-54.2M | ||
| EBITDA | $-71.8M | $-105.2M | $-128.6M | $-72.6M | $-44.3M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $9.0K | $19.0K | $198.0K | $-10.6M | $-12.9M | ||
| Intinc | $46.0K | $3.8M | $9.3M | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $46.0K | $3.8M | $9.3M | $10.6M | $12.9M | ||
| Gain on Sale of Securities | -- | -- | $-131.0K | -- | -- | ||
| Other Income/Expense | $960.0K | $119.0K | $-24.0K | $-11.0M | $-59.0K | ||
| Other Special Charges | $-960.0K | -- | $8.3M | $11.0M | $14.5M | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | -- | -- | -- | $170.0K | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-73.9M | $-108.9M | $-134.8M | $-80.7M | $-52.7M | ||
| Pre-Tax Income | $-74.0M | $-108.5M | $-135.0M | $-70.1M | $-39.7M | ||
| INCOME TAX | |||||||
| Tax Provision | -- | -- | $338.0K | $2.6M | $-1.1M | ||
| NET INCOME | |||||||
| Net Income | $-74.0M | $-108.5M | $-135.4M | $-72.7M | $-38.6M | ||
| Net Income (Continuing Operations) | $-74.0M | $-109.0M | $-135.4M | $-72.7M | $-38.6M | ||
| Net Income (Discontinued Operations) | $-74.0M | $-108.5M | $-135.4M | $-72.7M | $-38.6M | ||
| Net Income (Common Stockholders) | $-74.0M | $-108.5M | $-135.4M | $-72.7M | $-38.6M | ||
| Normalized Income | $-58.4M | -- | -- | -- | $-40.9M | ||
| TOTALS | |||||||
| Total Expenses | $72.9M | $112.4M | $143.3M | $156.7M | $177.9M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $25.0M | $47.2M | $51.4M | $73.9M | $83.1M | ||
| Average Shares Outstanding (Diluted) | -- | $47.2M | $51.4M | $73.9M | $83.1M | ||
| Shares Outstanding | $46.6M | $49.4M | $50.2M | $61.5M | $80.0M | ||
| Basic EPS | $-2.96 | $-2.3 | $-2.63 | $-0.98 | $-0.46 | ||
| Basic EPS (Continuing Operations) | $-2.96 | $-2.3 | $-2.63 | $-0.98 | $-0.46 | ||
| Diluted EPS | $-2.96 | $-2.3 | $-2.63 | $-0.98 | $-0.46 | ||
| Diluted EPS (Continuing Operations) | -- | $-2.3 | $-2.63 | $-0.98 | $-0.46 | ||
| OTHER METRICS | |||||||
| Gain On Sale Of P P E | -- | $109.0K | $24.0K | -- | $59.0K | ||
| Insurance And Claims | -- | $449.0K | -- | -- | -- | ||
| Other Gand A | $15.7M | $27.8M | $32.0M | $35.2M | $36.4M | ||
| Other Taxes | -- | -- | -- | $-170.0K | $-47.0K | ||
| Rent And Landing Fees | $2.3M | $-449.0K | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | $-170.0K | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GLUE | $19.20 | +2.1% | 694.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Monte Rosa Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW